LONDON (Alliance News) - Physiomics PLC Monday said it has signed a contract with a new speciality pharmaceuticals customer to investigate how one of the client's new candidate drugs shrinks tumours.
Physiomics scientists will use systems biology approaches to map the possible pathways by which the drug could act, it said in a statement without giving any financial details. The analysis will be used to narrow down possible mechanisms and suggest new experiments that the client can perform to home in on one mechanism.
"If successful, the directors hope that Physiomics will be able to offer its other modelling services to this new client as the project progresses," the company said in a statement.
Physiomics shares were up 31.6% at 0.25 pence early Monday, the biggest gainer on AIM.
By Steve McGrath; stevemcgrath@alliancenews.com; @SteveMcGrath1
Copyright 2013 Alliance News Limited. All Rights Reserved.


(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:


(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported...


(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Friday and not separately reported by Alliance ...


(Sharecast News) - Physiomics announced the appointment of Mark Davies as its head of quantitative pharmacology and data science on Monday.


(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Friday and not separately reported by Alliance News:


(Alliance News) - Physiomics PLC on Tuesday said that it has been awarded a new contract by an existing, large pharmaceutical client.


(Sharecast News) - Physiomics, a specialist in mathematical modelling and data science for drug development and personalised medicine, announced on Tu...


(Sharecast News) - Physiomics, a specialist in mathematical modelling and data science for drug development and personalised medicine, announced on Tu...


(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:


(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: